Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.

 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html  

 

The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:

Key Geographical Regions

  • Eastern China
  • Southern China
  • Northern China

Type of Product

  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

 

The China Pharmaceutical Contract Manufacturing Services Market, 2020-2030. report features the following companies, which we identified to be key players in this domain: 

  • 2Y-Chem
  • Aurisco Pharmaceutical
  • ChemPartner
  • Dorrapharma
  • Hubei Biocause Pharmaceutical
  • Infoark
  • Ningbo Menovo Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • STA Pharmaceutical
  • Zhejiang Huahai Pharmaceutical

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

4. Case Study: Comparison of Small Molecules and Large Molecules

5. Market Overview

6. Manufacturing Facilities of Pharmaceutical CMOs in China

7. Pharmaceutical Manufacturing Regulations in China

8. Company Profiles

9. Big Pharma Initiatives in China

10. Recent Trends

11. Capacity Analysis

12. SWOT Analysis

13. Market Forecast

 

14. Case Study: Impact of Coronavirus Outbreak

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe